@article{b5404a56d0854be289041bcb1bba5b6d,
title = "Genetic schizophrenia risk variants jointly modulate total brain and white matter volume",
abstract = "Background: Thousands of common single nucleotide polymorphisms (SNPs) are weakly associated with schizophrenia. It is likely that subsets of disease-associated SNPs are associated with distinct heritable disease-associated phenotypes. Therefore, we examined the shared genetic susceptibility modulating schizophrenia and brain volume. Methods: Odds ratios for genome-wide SNP data were calculated in the sample collected by the Psychiatric Genome-wide Association Study Consortium (8690 schizophrenia patients and 11,831 control subjects, excluding subjects from the present study). These were used to calculate individual polygenic schizophrenia (risk) scores in an independent sample of 152 schizophrenia patients and 142 healthy control subjects with available structural magnetic resonance imaging scans. Results: In the entire group, the polygenic schizophrenia score was significantly associated with total brain volume (R2=.048, p=1.6×10-4) and white matter volume (R2=.051, p=8.6×10-5) equally in patients and control subjects. The number of (independent) SNPs that substantially influenced both disease risk and white matter (n=2020) was much smaller than the entire set of SNPs that modulated disease status (n=14,751). From the set of 2020 SNPs, a group of 186 SNPs showed most evidence for association with white matter volume and an explorative functional analysis showed that these SNPs were located in genes with neuronal functions. Conclusions: These results indicate that a relatively small subset of schizophrenia genetic risk variants is related to the (normal) development of white matter. This, in turn, suggests that disruptions in white matter growth increase the susceptibility to develop schizophrenia.",
keywords = "Endophenotype, SNPs, genome-wide, imaging, psychiatric, structural MRI",
author = "{Psychiatric Genome-wide association study (GWAS) Consortium} and {Terwisscha Van Scheltinga}, {Afke F.} and Bakker, {Steven C.} and {Van Haren}, {Neeltje E.M.} and Derks, {Eske M.} and Buizer-Voskamp, {Jacobine E.} and Boos, {Heleen B.M.} and Wiepke Cahn and {Hulshoff Pol}, {Hilleke E.} and Stephan Ripke and Ophoff, {Roel A.} and Kahn, {Ren{\'e} S.} and Stephan Ripke and Sanders, {Alan R.} and Kendler, {Kenneth S.} and Levinson, {Douglas F.} and Pamela Sklar and Holmans, {Peter A.} and Lin, {Dan Yu} and Jubao Duan and Ophoff, {Roel A.} and Andreassen, {Ole A.} and Edward Scolnick and Sven Cichon and {St. Clair}, David and Aiden Corvin and Hugh Gurling and Thomas Werge and Dan Rujescu and Blackwood, {Douglas H.R.} and Pato, {Carlos N.} and Malhotra, {Anil K.} and Shaun Purcell and Frank Dudbridge and Neale, {Benjamin M.} and Lizzy Rossin and Visscher, {Peter M.} and Danielle Posthuma and Ruderfer, {Douglas M.} and Ayman Fanous and Hreinn Stefansson and Stacy Steinberg and Mowry, {Bryan J.} and Vera Golimbet and {De Hert}, Marc and J{\"o}nsson, {Erik G.} and Istv{\'a}n Bitter and Pietil{\"a}inen, {Olli P.H.} and Collier, {David A.} and Sarah Tosato and Nadine Norton",
note = "Funding Information: This work was supported by a Veni grant from Zorg Onderzoek Nederland, Medische Wetenschappen to SCB (the Dutch organization for health research and development, project number: 91686137), by a grant from the Dutch Brain Foundation to SCB [Grant 14F06(2)-34], and by Top Institute Pharma (project T5-203). The Genetic Risk and Outcome of Psychosis project was supported by a Grant from Zorg Onderzoek Nederland, Medische Wetenschappen, within the Mental Health program (project number: 10.000.1001). Genome-wide association study of this sample was funded by the National Institute of Mental Health (Grant RO1 MG078075 to RAO). ",
year = "2013",
month = mar,
day = "15",
doi = "10.1016/j.biopsych.2012.08.017",
language = "English (US)",
volume = "73",
pages = "525--531",
journal = "Biological psychiatry",
issn = "0006-3223",
publisher = "Elsevier USA",
number = "6",
}